載入中
NASDAQHealthcareMedical - Diagnostics & Research
最新資料
US$22.345
−US$0.245 · -1.08%
Precipio, Inc., based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood cancers. Its advanced offerings include IV-Cell, a unique cell culture media capable of simultaneously growing four types of hematopoietic cell lineages, and HemeScreen, a comprehensive collection of genetic diagnostic panels. Precipio also develops COVID-19 antibody tests. A notable proprietary innovation is ICE-COLD PCR, a patented technology designed to boost the sensitivity of molecular tests, with kits for this technology also sold to biopharmaceutical customers. Additionally, Precipio, Inc. collaborates with academic institutions dedicated to cancer research, diagnosis, and therapy.
一般交易時段
US$22.345
−US$0.245 · -1.08%
盤中時間採用ET。市場資料可能有所延遲。
Precipio, Inc., based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood cancers. Its advanced offerings include IV-Cell, a unique cell culture media capable of simultaneously growing four types of hematopoietic cell lineages, and HemeScreen, a comprehensive collection of genetic diagnostic panels. Precipio also develops COVID-19 antibody tests. A notable proprietary innovation is ICE-COLD PCR, a patented technology designed to boost the sensitivity of molecular tests, with kits for this technology also sold to biopharmaceutical customers. Additionally, Precipio, Inc. collaborates with academic institutions dedicated to cancer research, diagnosis, and therapy.
日內區間
目前US$22.345
52週區間
目前US$22.345
盤中時間採用ET。市場資料可能有所延遲。
Precipio, Inc., based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood cancers. Its advanced offerings include IV-Cell, a unique cell culture media capable of simultaneously growing four types of hematopoietic cell lineages, and HemeScreen, a comprehensive collection of genetic diagnostic panels. Precipio also develops COVID-19 antibody tests. A notable proprietary innovation is ICE-COLD PCR, a patented technology designed to boost the sensitivity of molecular tests, with kits for this technology also sold to biopharmaceutical customers. Additionally, Precipio, Inc. collaborates with academic institutions dedicated to cancer research, diagnosis, and therapy.
日內區間
目前US$22.345
52週區間
目前US$22.345
近期已公布業績
近期已公布業績
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2023年9月22日 | 1:20 | — | — |
股票分割 | 2019年4月29日 | 1:15 | — | — |
股票分割 | 2017年6月13日 | 1:30 | — | — |
股票分割 | 2014年1月28日 | 1:12 | — | — |
已生效 2023年9月22日
1:20
已生效 2019年4月29日
1:15
已生效 2017年6月13日
1:30
已生效 2014年1月28日
1:12
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI96.59萬0.00%2.3兆 USD0.03%US$380.95-0.16%
Vanguard Extended Market ETFVXF49萬0.00%954億 USD0.05%US$232.01-0.65%
iShares Micro-Cap ETFIWC11.54萬0.01%13.17億 USD0.60%US$180.27-0.77%
U.S. Micro Cap Portfolio ETFDFMC6.05萬0.00%75.44億 USD0.43%US$57.5324-0.29%
Dimensional - US Small Cap ETFDFAS4.12萬0.00%338.04億 USD0.31%US$78.025-0.19%
Dimensional - US Sustainability Core 1 ETFDFSU2.28萬0.00%23.92億 USD0.15%US$48.11-0.04%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR1.68萬0.00%455.76億 USD0.17%US$84.275-0.18%
Dimensional - US Core Equity 2 ETFDFAC1.34萬0.00%885.59億 USD0.21%US$45.28-0.07%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCU.S. Micro Cap Portfolio ETFDFMCDimensional - US Small Cap ETFDFASDimensional - US Sustainability Core 1 ETFDFSUU.S. Core Equity 1 Portfolio ETF Class SharesDCORDimensional - US Core Equity 2 ETFDFACAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
